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Abstract
Background: Exhaled nitric oxide (NO) production is increased in asthma and reflects the degree of airway
inflammation. The alveolar NO concentration (Calv) in interstitial pneumonia is reported to be increased. However,
it remains unknown whether NO production is increased and nitrosative stress occurs in eosinophilic pneumonia
(EP). We hypothesized that nitrosative stress markers including Calv, inducible type of NO synthase (iNOS), and 3-
nitrotyrosine (3-NT), are upregulated in EP.
Methods: Exhaled NO including fractional exhaled NO (FENO) and Calv was measured in ten healthy subjects, 13
patients with idiopathic pulmonary fibrosis (IPF), and 13 patients with EP. iNOS expression and 3-NT formation
were assessed by immunocytochemistory in BALf cells. The exhaled NO, lung function, and systemic inflammatory
markers of the EP patients were investigated after corticosteroid treatment for 4 weeks.
Results: The Calv levels in the EP group (14.4 ± 2.0 ppb) were significantly higher than those in the healthy
subjects (5.1 ± 0.6 ppb, p < 0.01) and the IPF groups (6.3 ± 0.6 ppb, p < 0.01) as well as the FENO and the
corrected Calv levels (all p < 0.01). More iNOS and 3-NT positive cells were observed in the EP group compared to
the healthy subject and IPF patient. The Calv levels had significant positive correlations with both iNOS (r = 0.858,
p < 0.05) and 3-NT positive cells (r = 0.924, p < 0.01). Corticosteroid treatment significantly reduced both the FENO
(p < 0.05) and the Calv levels (p < 0.01). The magnitude of reduction in the Calv levels had a significant positive
correlation with the peripheral blood eosinophil counts (r = 0.802, p < 0.05).
Conclusions: These results suggested that excessive nitrosative stress occurred in EP and that Calv could be a
marker of the disease activity.
Keywords: Alveolar nitric oxide, corticosteroid, fractional exhaled nitric oxide, inducible type of nitric oxide
synthase, 3-nitrotyrosine
Introduction
Eosinophilic pneumonia (EP) is an inflammatory lung
disease characterized by the infiltration of eosinophils
into the alveolar region and interstitium of the lung
[1,2]. The accumulation of eosinophils into the lung in
EP is reported to be induced by the excessive produc-
tion of eosinophil chemotactic mediators including
interleukin-5 (IL-5) [3,4], IL-18 [5], and granulocyte-
macrophage colony-stimulating factor (GM-CSF) [4].
Eosinophils contain a number of preformed mediators
and cytotoxic enzymes within cytoplasmic granules [6].
The most abundant preformed substances are major
basic protein (MBP), eosinophil cationic protein (ECP),
eosinophil derived neurotoxin (EDN), and eosinophil
peroxidase (EPO) [6]. In general, these mediators cause
desquamation and destruction of the epithelium, and
lead to airway and alveolar damage and lung dysfunction
[6]. Eosinophils also release superoxide anion, leuko-
trienes, and various kinds of cytokines that cause tissue
injury and inflammation. Thus, eosinophils are believed
to play a major role in the pathogenesis of eosinophilic
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inflammation occurring in EP remains unknown.
Eosinophils are key cells to induce airway inflamma-
tion of asthma [6], whereas oxidative/nitrosative stress
was recently reported to be related to the pathogenesis
of asthma [7,8]. Infiltrated eosinophils in the airways of
asthma express the inducible type of nitric oxide (NO)
synthase (iNOS), which generates higher amounts of
NO relative to the constitutive type of NOS (cNOS) [9].
Eosinophils also possess nicotinamide adenine dinucleo-
tide (NADPH) oxidase complex. Activated NADPH oxi-
dase catalyzes oxygen to superoxide anion, which enters
further redox pathways to generate hydrogen peroxide
i nt h ep r e s e n c eo fs u p e r o x i d ed i s m u t a s e ,o rh y d r o x y l
and nitrogen dioxide radicals, after combining with NO
[10]. NO rapidly reacts with superoxide anion to form
highly reactive nitrogen species (RNS) such as peroxyni-
trite [11]. Since excessive RNS cause tissue injury and
stimulate the production of proinflammatory cytokines
and chemokines [8,12], nitrosative stress could be one
of the factors responsible for airway inflammation in
asthma [8,13]. It has not been elucidated yet whether
nitrosative stress may occur in the lungs of patients
with EP.
In corticosteroid-naive asthmatic patients, the exhaled
NO levels are markedly elevated compared to those in
healthy subjects [14]. It has been reported that the
levels of fractional exhaled NO (FENO) have significant
correlations with eosinophilic inflammation [15] and
airway hyperresponsiveness in asthma [16]. Recently,
the local NO production could be determined by parti-
tioning exhaled NO into the alveolar NO concentration
(Calv) and the conducting airway wall flux of NO
(JawNO), and the Calv levels were found to reflect the
NO production at the lung parenchyma [17]. In fact,
the Calv levels were elevated in patients with alveolitis
including hypersensitivity pneumonitis and idiopathic
pulmonary fibrosis (IPF) compared to those in asth-
matics and healthy subjects [18]. If the Calv levels in EP
are elevated, it might indicate that the excessively gen-
erated NO in the lung parenchyma induces nitrosative
stress in EP.
The aim of this study, therefore, was to investigate
NO production and the resulting nitrosative stress in
EP. Furthermore, we examined whether the Calv levels
changed during treatment with systemic corticosteroid
to assess whether it can be a marker of the response by
treatment. To accomplish this, healthy subjects and
patients with IPF and EP were enrolled in the current
study. We investigated the exhaled NO production
including FENO and Calv. iNOS expression and 3-nitro-
tyrosine (3-NT) formation, a footprint of RNS produc-
tion, were assessed in the cells of bronchoalveolar
lavage fluid (BALf) as nitrosative stress markers. We
investigated the correlation between the exhaled NO
levels and lung function or systemic inflammatory mar-
kers such as peripheral blood eosinophil counts and C-
reactive protein (CRP). In addition, we assessed whether
the magnitude of reduction in Calv was correlated with
that in systemic inflammatory markers during corticos-
teroid treatment.
Methods
Subjects
Thirteen patients with EP, 13 patients with IPF, and 10
healthy subjects took part in the present study after giv-
ing written informed consent. All subjects were never-
or ex-smokers. None of the subjects had been treated
with systemic and/or inhaled corticosteroids. All the
patients with EP had acute or chronic respiratory symp-
toms including cough and sputum, pulmonary infiltrates
on chest X-ray test and CT scan. They had pulmonary
eosinophilia diagnosed by transbronchial lung biopsy
(TBLB) according to the criteria of American Thoracic
Society [2]. The patients with EP had no recurrent epi-
sodes of wheezing, no previous history of atopy and had
never been diagnosed with bronchial asthma. IPF was
diagnosed by pulmonary function tests, chest X-ray, and
CT scan according to the criteria of the American Thor-
acic Society [19]. These patients had had restrictive ven-
tilatory defect, interstitial infiltrates such as ground glass
opacity and honey combing on CT scan and had no
clinical history of exposure to hazardous environmental
agents. Healthy subjects had normal lung function, no
abnormality in chest X-ray, and no respiratory symp-
toms. None of the subjects had had a respiratory tract
infection in the month preceding the study. This study
was approved by the ethics committee of Wakayama
Medical University.
Study design
Exhaled NO including FENO and Calv were measured
according to previous studies [17,20]. All subjects
received pulmonary function tests by CHESTAC (Chest
Co. Ltd., Tokyo, Japan). All EP patients underwent
bronchoscopy. One IPF patient and one healthy subject
also received bronchoscopy. Eight of 13 EP patients
were treated with systemic predonisolone (1mg/kg/day)
for four weeks, with the dose of corticosteroid decreased
gradually and finally discontinued within the first 6
months according to the previous guideline [2]. The
treatment was started as a part of the routine treatment.
Clinical symptoms, chest X-ray findings and the results
of the blood examination were appropriately assessed to
evaluate the effects of corticosteroid treatment. After
corticosteroid treatment for 4 weeks, the exhaled NO
and the pulmonary function were assessed. Peripheral
eosinophil counts and CRP levels were also investigated.
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FENO was measured according to the criteria of the
American Thoracic Society using a chemiluminescence
analyzer (NA-623N; Kimoto Electric, Osaka, Japan) [20].
Briefly, the subject exhaled at a positive constant mouth
pressure (15 cmH2O) from the total lung capacity level.
The FENO was determined at a constant flow rate of 50
ml/s. The exhaled flow rates were verified at 50, 100,
175, and 370 ml/s to calculate the Calv according to a
previous study [17]. For each flow rate, at least two
technically adequate measurements were performed.
Calv and JawNO were calculated with the two compart-
ment model of NO exchange [17]. Moreover, we calcu-
lated the corrected Calv using the trumpet model with
axial diffusion [21].
BAL and TBLB
Fiberoptic bronchoscopy, BAL and TBLB were per-
formed as previously described [22]. The obtained
BALfs were immediately centrifuged at 650 x g for 5
min at 4 °C. The supernatant was stored at -80 °C. The
cells in the BALfs were counted by hemocytometer and
the cell viability was determined by the trypan blue
exclusion method. A 100 μl aliquot of the suspension
was placed into the cups of a Shandon 4 cytocentrifuge
(Shandon Southern Instruments, Sewickley, PA) and five
slides were obtained from each sample. The cell differ-
ential count was made after the staining with Diff-Quik
(Sysmex Co.Ltd., Kobe, Japan). The obtained lung tis-
sues were fixed by 10% formalin and sliced 4 micro-
meter thickness. The slides were stained by hematoxylin
and eosin staining and photographed with a digital cam-
era (DMX-1200C; Nikon, Tokyo, Japan) under ×400
magnification.
Immunocytostaining
Immunocytostaining for iNOS or 3-NT in BALf cells
was performed as previously described [23]. Briefly, the
cells were fixed in 4% paraformaldehyde fixative solution
for 30 min at room temperature. After blocking endo-
genous peroxidase, the samples were incubated with
blocking reagents containing 0.3% Triton-X (Dako Cyto-
mation, Kyoto, Japan) to reduce non-specific binding of
antibodies for 30 min at room temperature. The cells
were incubated with anti-iNOS rabbit antisera (1:200
dilution; Wako Pure Chemical Industries, Osaka, Japan)
or anti-nitrotyrosine rabbit polyclonal antibody (1:100
dilution; Upstate Biotechnology, Lake Placid, NY) at 4 °
C overnight. After being washed, the cells were incu-
bated with secondary antibodies (ENVISION polymer
reagent, Dako Cytomation, Kyoto, Japan). The diamino-
benzidine reaction was performed and followed by
counterstaining with hematoxylin. The cells were viewed
by microscopy (E-800; Nikon, Tokyo, Japan) and
photographed with a digital camera (DMX-1200C;
Nikon, Tokyo, Japan) under ×400 magnification. Two
investigators examined more than 500 cells and counted
iNOS or 3-NT immunopositive cells without prior
knowledge of the disease. The mean values were used
for analysis.
Collection of exhaled breath condensate (EBC)
The EBCs were collected from the healthy subjects and
patients with IPF and EP using a condenser, which per-
mitted the noninvasive collection of condensed exhaled
air by freezing it to -20°C (Eco-screen; Jaeger, Hoech-
berg, Germany) according to the criteria of the Eur-
opean Respiratory Society [24]. The obtained EBC was
stored at -80°C until later assay.
Cytokine measurements in EBC
T h ee x p r e s s i o no f4 2d i f f e r e n tc y t o k i n e si nE B Cw a s
investigated by Human Cytokine Antibody III kit (Ray
Biotech Inc., Norcross, GA) according to the manufac-
turer’s instructions.
Statistical analysis
Data were expressed as mean ± SEMs. Experiments with
multiple comparisons were evaluated by one way
ANOVA followed by the Scheffe’s test. Spearman’sc o r -
relation analysis was performed to assess the correlation.
Probability values of less than 0.05 were considered
significant.
Results
Ten healthy subjects, 13 patients with IPF, and 13
patients with EP took part in the present study. The
characteristics of the study subjects are given in Table 1.
Although the patients with IPF and EP had significantly
lower vital capacity % predicted (%VC) than the healthy
subjects, and the patients with IPF had significantly
lower total lung capacity % predicted (%TLC), functional
residual capacity % predicted (%FRC), residual volume
(RV), RV % predicted (%RV), and diffusion lung carbon
monoxide % predicted (%DLCO) than the patients with
EP, there was no significant difference in other values of
lung function among three groups. Although eosinophil
counts in BALf were not so high in some patients with
EP in this study, eosinophil infiltration into the alveolar
septa was observed in the lung tissues from all EP
patients (Additional file 1, Figure S1).
Exhaled NO levels in the study subjects
The FENO levels in the EP group (35.0 ± 5.2 ppb) were
significantly higher than in the healthy subject group
(17.8 ± 2.2 ppb, p < 0.01) and the IPF group (20.8 ± 1.8
ppb, p < 0.01, Figure 1A). Because eosinophilic inflam-
mation occurs in the lung parenchyma in EP, we
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elevated compared to the other two groups. As we
expected, the Calv levels in the EP group (14.4 ± 2.0
ppb) were markedly higher than in the healthy subject
(5.1 ± 0.6 ppb, p < 0.01) and the IPF groups (6.3 ± 0.6
p p b ,p<0 . 0 1 ,F i g u r e1 B ) .J a w N Ow a sa l s oc a l c u l a t e d
with a two compartment model. There was no signifi-
cant difference among the three groups (Figure 1C). To
avoid the influence of contamination from NO produced
in the airways to Calv, we also calculated the corrected
Calv. The corrected Calv levels in the EP group (13.3 ±
2.0 ppb) were significantly higher than those in both the
healthy subjects (4.5 ± 0.6 ppb, p < 0.01) and the IPF
groups (5.3 ± 0.6 ppb, p < 0.01, Figure 1D).
iNOS expression and nitrosative stress in EP
Cell differential counts in the BALf of the study subjects
are listed in Additional file 2, Table S1. To investigate
the source of increased NO production in the exhaled
air from the patients with EP, we performed immunos-
taining for iNOS in the BALf cells. More iNOS positive
cells were observed in the patients with EP than in the
healthy subject and IPF patient (Figure 2A-C, Additional
file 3, Table S2). There were significant positive correla-
tions between the proportion of iNOS positive cells and
the FENO levels (r = 0.913, p < 0.01, Figure 2D), JawNO
levels (r = 0.869, p < 0.05), or the Calv levels (r = 0.858,
p < 0.05, Figure 2E). More 3-NT positive cells were also
observed in the patients with EP than in the healthy
subject and IPF patient (Figure 3A-C, Additional file 3,
Table S2). There were significant positive correlations
between the proportion of 3-NT positive cells and the
FENO levels (r = 0.890, p < 0.01, Figure 3D), JawNO
levels (r = 0.790, p < 0.05), or the Calv levels (r = 0.924,
p < 0.01, Figure 3E). The proportion of iNOS positive
cells was significantly correlated with that of 3-NT posi-
tive cells (r = 0.919, p < 0.01, Figure 4).
Correlation between the exhaled NO levels and lung
function or inflammatory markers
We examined the correlation between the exhaled NO
levels and the values of lung function and systemic
inflammatory markers in the patients with EP before
systemic steroid treatment (Table 2). There were signifi-
cant correlations between the Calv levels and VC (r =
-0.670, p < 0.05), %VC (r = -0.645, p < 0.05), forced
expiratory volume in one second (FEV1.0)( r=- 0 . 6 6 2 ,p
< 0.05) or peripheral blood eosinophil counts (r = 0.658,
p < 0.05).
Analysis of cytokine and chemokine profile in EBC
EBCs were obtained from nine healthy subjects, eleven
IPF patients and nine EP patients. We examined the
expression of 42 different cytokines in EBC using a cyto-
kine assay method. The cytokine and chemokine profil-
ing are summarized in Additional file 4, Table S3. There
was no significant difference in their expression among
the 3 groups.
The effects of corticosteroid treatment on nitrosative
stress in the patients with EP
To elucidate whether the exhaled NO levels in EP
changes during systemic corticosteroid treatment, we
measured the exhaled NO levels as well as lung function
and systemic inflammatory markers before/after treat-
ment with systemic corticosteroid. All patients’ symp-
toms and chest radiographic findings were completely
improved by corticosteroid treatment for 4 weeks. After
corticosteroid treatment, the FENO (44.1 ± 4.7 ppb vs
27.3 ± 2.1 ppb, p < 0.05) and the Calv levels (15.1 ± 2.4
ppb vs 6.90 ± 0.87 ppb, p < 0.01) were significantly
reduced (Table 3). As expected, among the lung func-
tion tests, the VC (2.46 ± 0.38 L vs 2.96 ± 0.34 L, p <
0.01) and %VC (83.6 ± 11% vs 100 ± 11%, p < 0.01)
values were significantly restored (Table 3). Peripheral
blood eosinophil counts (584 ± 210/μl vs 45.4 ± 13/μl, p
< 0.01) and CRP levels (1.91 ± 1.0 mg/dl vs 0.348 ± 0.29
mg/dl, p < 0.05) were also significantly reduced (Table
3). To determine whether the exhaled NO reflects the
lung inflammation in EP, we investigated the correlation
between the degree of reduction in the exhaled NO
levels and those in the values of lung function and
Table 1 Characteristics of the study subjects
HS IPF EP
Number (M/F) 10(4/6) 13(12/1) 13(7/6)
Age (yrs ) 60.9 ± 4.5 69.5 ± 1.9 63.2 ± 3.6
Smoking status (never-/ex-/
current smoker)
(6/4/0) (1/12/0) (8/5/0)
VC (L) 3.20 ± 0.18 2.94 ± 0.23 2.57 ± 0.25
%VC (%) 108 ± 3.6 87.0 ± 5.8* 86.9 ± 7.0*
FEV1.0 (L) 2.54 ± 0.16 2.40 ± 0.16 2.08 ± 0.18
FEV1.0% (%) 80.5 ± 2.6 80.8 ± 1.6 82.4 ± 2.5
TLC (L) N.D. 4.04 ± 0.32 4.61 ± 0.45
%TLC (%) N.D 73.7 ± 6.0 96.5 ± 7.1
†
FRC (L) N.D. 2.40 ± 0.14 2.86 ± 0.24
%FRC (%) N.D 74.9 ± 6.5 97.8 ± 6.9
†
RV (L) N.D. 1.34 ± 0.13 1.90 ±
0.19
†
%RV (%) N.D. 66.4 ± 9.9 115 ± 14
†
%DLCO (%) N.D. 66.7 ± 5.4 91.5 ± 11
†
%DLCO/VA (%) N.D. 73.6 ± 5.4 86.7 ± 6.1
HS = healthy subject; IPF = idiopathic pulmonary fibrosis; EP = eosinophilic
pneumonia; VC = vital capacity; %VC = VC % predicted; FEV1.0 = forced
expiratory volume in one second; TLC = total lung capacity; %TLC = TLC %
predicted; FRC = functional residual capacity; %FRC = FRC % predicted; RV =
residual volume; %RV = RV % predicted; %DLCO = diffusion lung carbon
monoxide % predicted; %DLCO/VA =D LCO/alveolar volume % predicted; N.D. =
not done. *p < 0.05 compared with the values of HS group;
†p < 0.05
compared with the values of IPF group.
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treatment (Table 4). There was a significant positive
correlation between the magnitude of the steroid-
mediated reduction in the Calv levels and the peripheral
blood eosinophil counts (r = 0.802, p < 0.05).
Discussion
The present study demonstrated that the Calv levels in
the patients with EP were significantly higher than those
in the healthy subjects and the patients with IPF. We
also demonstrated that more iNOS positive cells and 3-
NT positive cells in the BALf were observed in EP than
in IPF and healthy subject. The proportion of both the
iNOS-positive cells and the 3-NT positive cells in the
BALf was significantly correlated with the exhaled NO
levels. Especially, the Calv levels had significant correla-
tions with VC,%VC, FEV1.0, or peripheral blood eosino-
phil counts before steroid treatment. Systemic
corticosteroid treatment reduced the Calv and the FENO
levels. The magnitude of the steroid-mediated reduction
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Figure 1 Exhaled nitric oxide (NO) levels in the study subjects. Panels show the fractional exhaled NO (FENO) levels (A), the alveolar NO
(Calv) levels (B), airway wall NO (JawNO) (C), and corrected Calv (D). Horizontal lines represent the mean value of the exhaled NO levels. HS =
healthy subject; IPF = idiopathic pulmonary fibrosis; EP = eosinophilic pneumonia; N.S = not significant.
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in the peripheral blood eosinophil counts. These results
suggest that more nitrosative stress occurred in the EP
patients compared to those in the IPF patients and Calv
might be a marker of the response by treatment.
In inflammatory conditions, excessive NO was pro-
duced by iNOS as well as superoxide anion by NADPH
oxidase or xanthine oxidase [8,11]. NO reacts with
superoxide anion to produce the highly reactive RNS
[11]. RNS are also generated via the H2O2/peroxidase-
dependent nitrite oxidation pathway [25]. These RNS
cause tissue damage due to active protease or toxic moi-
eties released by stimulated inflammatory cells. RNS also
augment plasma leakage and alter the function of sev-
eral proteins by the nitration of tyrosine residues [8,26].
Furthermore, RNS augment tissue remodeling through
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Figure 2 Immunocytochemical detection of the inducible type of NO synthase (iNOS) in the bronchoalveolar lavage fluid (BALf) cells.
Representative photographs are shown in panel A (healthy subject: HS); B (idiopathic pulmonary fibrosis: IPF); and C (eosinophilic pneumonia:
EP). iNOS immunopositivity in BALf cells is correlated with FENO (D) and Calv levels (E). r is the correlation coefficient. The lines and p values
correspond to the fitted regression equation.
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transforming growth factor-beta (TGF-b)p a t h w a y
[27,28]. This is the first study to investigate oxidative
and/or nitrosative stress in EP. In the current study,
more 3-NT positive cells were observed in the BALf of
EP patients, suggesting that more nitrosative stress
occurred in EP. Because of the powerful inflammatory
effects of RNS, nitrosative stress may be related to the
inflammation that occurs in EP.
RNS, including NO and peroxynitrite derived from
iNOS, have been reported to cause tissue inflammation
in various kinds of diseases [8,29]. Although the precise
mechanism is unknown, RNS may be involved in the
pathogenesis of EP through the following mechanisms.
First, endogenous NO could stimulate eosinophil migra-
tion in a rodent model because NOS inhibitors inhibit
eosinophil infiltration into the tissues [13,30]. Moreover,
Hebestreit et al. demonstrate that endogenous NO
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Figure 3 Immunocytochemical detection of the 3-nitrotyrosine (3-NT) in the BALf cells. Representative photographs are shown in panel A
(healthy subject: HS); B (idiopathic pulmonary fibrosis: IPF); and C (eosinophilic pneumonia: EP). 3-NT immunopositivity in BALf cells is correlated
with FENO (D) and Calv levels (E). r is the correlation coefficient. The lines and p values correspond to the fitted regression equation.
Furukawa et al. Respiratory Research 2011, 12:81
http://respiratory-research.com/content/12/1/81
Page 7 of 11could prolong eosinophil survival induced by Fas ligand-
induced apoptosis [31]. These findings suggested that
RNS might play a key role in eosinophilic inflammation
in EP. Second, RNS induce microvascular hyperperme-
ability [13] as well as tissue remodeling through matrix
metalloproteinases (MMPs) activation and fibroblast-
mediated tissue fibrosis [27,32]. Because EP is one of
the interstitial lung diseases, the lung tissue remodeling
observed in EP may be partially mediated by RNS.
Nitrosative stress might be involved in the pathogenesis
of EP, but further study is needed to clarify these
mechanisms.
We demonstrated that the Calv levels in the EP
patients were higher than those in the healthy subjects
and the IPF patients, whereas there was no significant
difference in the JawNO levels among the three groups.
The JawNO levels in the EP group correlated with the
iNOS positive cell counts. However, we also calculated
the levels of the corrected Calv, which avoided contami-
nation by the NO produced in the airways. The cor-
rected Calv levels in the patients with EP were higher
than in the other two groups, suggesting that the
increase of exhaled NO (i.e. FENO) in the EP patients
could be attributed to increased NO production from
the peripheral lung (i.e. Calv).
In the present study, there was a good correlation
between the iNOS positive cells and the exhaled NO levels
including Calv and FENO. These findings suggest that
iNOS might be the source of the exhaled NO in the
patients with EP. According to the immunocytochemistory
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Figure 4 Correlation between iNOS immunopositivity and 3-NT immunopositivity in the BALf cells. r is the correlation coefficient. The
lines and p values correspond to the fitted regression equation.
Table 2 Correlation between the exhaled nitric oxide
levels and lung function, systemic inflammatory markers
and eosinophils in BALf
FENO Calv
r p value r p value
VC (L) - 0.270 0.372 - 0.670 0.012*
%VC (%) - 0.111 0.718 - 0.645 0.017*
FEV1.0 (L) - 0.248 0.414 - 0.662 0.014*
FEV1.0% (%) 0.254 0.403 0.240 0.431
%DLCO (%) - 0.057 0.853 - 0.316 0.272
%DLCO/VA (%) - 0.258 0.395 -0.018 0.953
Eosinophils (/μl) 0.379 0.201 0.658 0.015*
CRP (mg/dl) -0.358 0.229 -0.057 0.853
Eosinophils in BALf (%) -0.183 0.638 -0.060 0.878
NO = nitric oxide; BALf = bronchoalveolar lavage fluid; FENO = fractional
exhaled NO; Calv = alveolar NO concentration; CRP = C-reactive protein. r =
correlation coefficient, p values correspond to the fitted regression equation.
*p < 0.05.
Table 3 Changes in the exhaled NO levels, lung function
and systemic inflammatory markers during steroid
treatment
pre post p value
FENO (ppb) 44.1 ± 4.7 27.3 ± 2.1 p = 0.021*
Calv (ppb) 15.1 ± 2.4 6.90 ± 0.87 p = 0.008**
VC (L) 2.46 ± 0.38 2. 96 ± 0.34 p = 0.008**
%VC (%) 83.6 ± 11 100 ± 11 p = 0.008**
FEV1.0 (L) 1.96 ± 0.24 2.12 ± 0.23 p = 0.11
FEV1.0% (%) 82.2 ± 3.9 78.2 ± 4.6 p = 0.47
%FEV1.0 (%) 82.0 ± 9.1 91.2 ± 9.0 p = 0.25
%DLCO (%) 92.4 ± 18 113 ± 15 p = 0.11
%DLCO/VA (%) 79.4 ± 6.8 85.3 ± 5.1 p = 0.47
eosinophil (/μl) 584 ± 210 45.4 ± 13 p = 0.008**
CRP (mg/dl) 1.91 ± 1.0 0.348 ± 0.29 p = 0.016*
pre = pre steroid treatment; post = post steroid treatment; p values compared
with the values of pre steroid treatment. * p < 0.05, ** p < 0.01
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immunoreactivity suggesting that these cells may be the
major source of NO production. Recently, Brindicci et al.
demonstrated that both iNOS and neuronal NOS (nNOS)
expression were enhanced in the lung peripheral tissues
from chronic obstructive pulmonary disease (COPD)
patients [33]. Therefore, the source of increased alveolar
NO production (i.e. Calv) observed in this study could be
mediated by iNOS and nNOS. Unfortunately, we could
not obtain lung tissue from the patients, and we did not
investigate nNOS and endothelial NOS (eNOS) expression
in the BALf cells. It remains unclear which isoform of
NOS is responsible for the elevated Calv levels. As shown
in Figure 4, there was a very good correlation between the
iNOS positive cells and the 3-NT positive cells suggesting
that iNOS might be responsible for the RNS production.
Since the mechanism for upregulation of iNOS is still
unknown, further study is needed.
Corticosteroids have a number of anti-inflammatory
actions including the suppression of iNOS expression
[34]. In the current study, systemic corticosteroid treat-
ment improved the clinical symptoms, chest radiographic
findings, and inflammatory markers. It reduced the Calv
levels almost to within the normal range. The reduction
in the Calv levels might be due to the suppression of
iNOS expression. Because nitrosative stress causes lung
inflammation, the therapeutic effects of corticosteroid on
EP may be mediated partially through the suppression of
nitrosative stress. There were significant correlations
between the Calv levels and lung function or peripheral
blood eosinophil counts (Table 2). Interestingly, there
was a good correlation between the magnitude of the
steroid-mediated reduction in the Calv levels and that in
the peripheral blood eosinophil counts (Table 4). These
findings suggest that Calv may be a good biomarker of
the disease activity in EP. Because Calv measurement is
an easy and noninvasive method, it might be useful for
assessing the degree of lung inflammation in EP.
Alveolar NO concentration (Calv [ppb]) is described
by the following formula
Calv = VNO,alv/DLNO (1)
where VNO,alv [nl/s] is NO diffusing rate from tissue to
alveolar air and DLNO [nl/s/ppb] is NO diffusing capa-
city from alveolar space to pulmonary vessels [18]. As
DLNO is approximately 4* DLCO [18], the equation (1)
can be rearranged to
Calv = VNO,alv/4*DLCO (2)
Hence, the values of Calv are affected by VNO,alv and
DLCO. Calv can be increased because of the increased NO
production in lung parenchyma causing increased NO dif-
fusion to alveolar air (i.e. VNO,alv), or because of decreased
diffusion of NO from the alveolar air to pulmonary blood
stream caused by decreased alveolar NO diffusing capacity
(i.e. DLNO =4 * D L CO). In the current study, the values of
DLCO in the EP group were better than those in the IPF
group (Table 1). Taken together, the “actual” NO produc-
tion in the lung parenchyma appeared to be increased
more in the patients with EP compared to the IPF patients.
Previous studies described that collecting EBC is a
noninvasive and repeatable method, and useful for mea-
suring airway inflammatory molecules in respiratory dis-
eases including asthma [35] and COPD [36]. There was
no difference in the expression of 42 cytokines and che-
mokines in EBCs (Additional file 4, Table S3), although
the Calv levels were markedly elevated in the EP group
compared to the IPF group and healthy subject group.
Thus, measurement of Calv could be extremely useful
for the assessment of lung inflammation in EP.
We used the IPF patients as disease controls in the
current study because EP is classified as interstitial
pneumonia. The current study is designed to address
whether Calv could be a noninvasive method for the dif-
ferential diagnosis of various interstitial pneumonias. As
previously reported, nitrosative stress occurs in the air-
ways of asthmatic patients [23]. In this study, the per-
centage of 3-NT immunopositive cells in BALf (33 ±
7%) from the EP patients was nearly the same as that in
the induced sputum (29 ± 4%) from asthmatic patients
[23]. Because the obtained samples differed between
these two studies, it is not easy to compare the degree
of nitrosative stress between EP and asthma.
As shown in Table 2, there were significant correla-
tions between the values of Calv and those of VC,%VC,
and FEV1.0. We expected that the Calv levels would
have a correlation with%DLCO because eosinophilic
inflammation is observed in the lung parenchyma in EP.
Patients with EP sometimes have a restrictive ventilatory
impairment. This is one possible explanation for the
correlation between the Calv levels and%VC. In the cur-
rent study, the actual values of FEV1.0 had a correlation
with the Calv levels. This was an unexpected finding for
us because the main site of inflammation in EP is the
lung parenchyma, not the airways. There was no
Table 4 Correlation between the changes in the exhaled
NO levels and those in lung function and systemic
inflammatory markers after steroid treatment
FENO(post/pre) Calv(post/pre)
r p value r p value
%VC (post/pre) -0.024 0.977 0.048 0.935
Eosinophils (post/pre) 0.108 0.793 0.802 0.022*
CRP (post/pre) -0.524 0.197 -0.691 0.069
post/pre = post steroid value/pre steroid value; r = correlation coefficient; p
values correspond to the fitted regression equation. * p < 0.05.
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values in previous studies [37,38]. Moreover, a correla-
tion was observed between the Calv levels and the actual
values of FEV1.0, not FEV1.0%. On the basis of these find-
ings, the reason why the Calv levels had a correlation
with the FEV1.0 values remains unknown.
We measured Calv only twice in this study. It would be
interesting to examine if there was any correlation of Calv
with the symptoms of the patients. However, it is difficult
to assess the symptom scores in EP as well as asthma con-
trol test. There was a significant correlation between the
changes in the Calv levels and the eosinophil counts after
steroid treatment as shown in Table 4. We believe that Calv
would be an extremely useful marker of the disease activity.
The limitations of the current study are as follows.
First, we failed to collect BALf samples from patients
with IPF and from healthy subjects. Because IPF is
sometimes worsened by the procedure for obtaining
BAL, we could not perform it. As for the healthy sub-
jects, most refused the BAL examination. A previous
study showed that low levels of iNOS as well as 3-NT
formation were expressed in inflammatory cells of lung
tissues from patients with the inactive stage of IPF and
healthy subjects [39]. Our iNOS and 3-NT immunos-
taining data are compatible with those of a previous
report [39]. Second, we could not obtain large size of
lung tissues from the EP patients, and therefore could
not investigate the expression of iNOS and 3-NT forma-
tion. Because airway and alveolar epithelial cells,
endothelial cells, and vascular smooth muscle cells have
been reported to express iNOS [8], these cells may also
contribute to the nitrosative stress.
In summary, our data demonstrate that excessive NO
production, presumably via iNOS, occurred in the patients
with EP. The nitrosative stress markers were well corre-
lated with the lung function and systemic inflammatory
markers. Corticosteroid treatment improved the Calv
levels as well as the clinical signs. The magnitude of the
steroid-mediated reduction in the Calv levels was corre-
lated with the peripheral blood eosinophil counts. Exces-
sive nitrosative stress occurred in the patients with EP
compared to the healthy subjects and the IPF patients and
may induce the inflammation observed in EP because of
the powerful proinflammatory effects of RNS. In addition,
Calv could be a useful marker of the symptoms, severity
and response to treatment in EP.
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